Medications for Systemic Onset Juvenile Chronic Arthritis

2 results
  • actemra - tocilizumab injection, solution, concentrate

    (Tocilizumab)
    Genentech, Inc.
    Actemra (tocilizumab) treats moderately to severely active rheumatoid arthritis, giant cell arteritis, SSc-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis (ages 2+), CAR T cell-induced cytokine release syndrome, and hospitalized COVID-19 patients requiring oxygen support or mechanical ventilation.
  • ilaris - canakinumab injection, solution

    (Canakinumab)
    Novartis Pharmaceuticals Corporation
    Ilaris treats periodic fever syndromes (CAPS, TRAPS, HIDS/MKD, FMF) in adults and children; active Still's Disease (AOSD and SJIA) in patients 2 and older; and gout flares in adults when NSAIDs and colchicine are contraindicated, not tolerated, or ineffective.